Among these, AG221 (Enasidenib, CC90007; Agios) reported targeting IDH2 mutations and is currently beneath improvement to treat gliomas, in addition to AG881 (a pan-IDH1/-2 (Agios) inhibitor which is being developed for the administration of gliomas cancers. This evidence concerns the gene IDH1 and glioma.